Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Walnut Intervention on Metabolic Syndrome (WIMS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Chinese Academy of Sciences.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
California Walnut Commission
Information provided by:
Chinese Academy of Sciences
ClinicalTrials.gov Identifier:
NCT00742742
First received: August 27, 2008
Last updated: March 27, 2009
Last verified: March 2009

August 27, 2008
March 27, 2009
March 2009
June 2009   (final data collection date for primary outcome measure)
Plasma Low-density-lipoprotein (LDL) cholesterol [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00742742 on ClinicalTrials.gov Archive Site
Total cholesterol, triglyceride, HDL-C, fasting glucose and insulin, HbA1C, blood pressure, CRP, IL-6, adiponectin, RBP4, E-selectin, ICAM-1, VCAM-1, and fatty acid profiles of the red blood cells. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Walnut Intervention on Metabolic Syndrome (WIMS)
The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome

The purpose of this study is to determine whether a daily supplement of 30 grams of walnut is effective in the treatment of metabolic syndrome (MetS).

Metabolic syndrome (MetS), a constellation of metabolic abnormalities including central obesity, dyslipidemia, elevated blood pressure and hyperglycemia, is associated with the development of type 2 diabetes and CVD. It has become one of the major public health challenges in China due to rapidly nutrition transition and the nature of obesity epidemic. Treatment of MetS in China is very important for the prevention of the epidemic of its consequences (such as CVD and type 2 diabetes).

Compelling evidence from recent human studies has demonstrated that diet and lifestyle modifications are effective means in MetS management. Walnut is a complex food source containing high amounts of polyunsaturated fatty acids (PUFA), as well as plant protein, Vitamin E and other substances that may have an impact on health. Therefore, the aim of this study is to investigate the effect of walnut supplementation on the management of MetS in adult Chinese men and women in a randomized, controlled clinical trial. A total of 200 participants with MetS (defined by IDF criteria) will be randomly assigned to a walnut-supplemented diet (30 grams/day) or an isocaloric control diet for 12 weeks. Effects of walnut supplementation will be evaluated by measuring metabolic profile (BMI, blood pressure, total cholesterol, triglyceride, LDL-C and HDL-C, fasting glucose and insulin, HbA1C), inflammatory markers (CRP and IL-6), markers of endothelial function (E-selectin, ICAM-1 and VCAM-1), and fatty acid profile.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Metabolic Syndrome X
  • Dietary Supplement: walnut
    30 grams/day supplement of walnut for 12 weeks
  • Behavioral: TLC diet education
    TLC diet education
  • Experimental: A
    TLC diet education + 30 grams/day supplement of walnut
    Interventions:
    • Dietary Supplement: walnut
    • Behavioral: TLC diet education
  • Sham Comparator: B
    TLC diet education
    Intervention: Behavioral: TLC diet education
Wu H, Pan A, Yu Z, Qi Q, Lu L, Zhang G, Yu D, Zong G, Zhou Y, Chen X, Tang L, Feng Y, Zhou H, Chen X, Li H, Demark-Wahnefried W, Hu FB, Lin X. Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome. J Nutr. 2010 Nov;140(11):1937-42. Epub 2010 Sep 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
September 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The International Diabetes Federation (IDF) criteria for the diagnosis of the MetS will be used. MetS will be defined with central obesity (defined as waist circumference ≥ 80 cm for women or ≥ 90 cm for men) plus any two of the following four factors:

    • Raised triglycerides level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality;
    • Reduced HDL cholesterol: < 40 mg/dL (1.0 mmol/L) in males and < 50 mg/dL (1.3 mmol/L) in females, or specific treatment for this lipid abnormality;
    • Elevated blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension;
    • Increased fasting plasma glucose (FPG): ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes.
  • Being able to comply with the specified feeding conditions
  • Being able to eat walnuts
  • Being between the ages of 35 and 60 years

Exclusion Criteria:

  • Pregnancy or lactation
  • Use of insulin
  • Severe kidney disease
  • Cardiovascular diseases, stroke, cancer and psychological disorders
  • Walnut allergies or frequently eating walnuts or other nuts (>90 grams/week)
  • Drug or alcohol abuse.
Both
35 Years to 60 Years
No
Contact: An Pan, MSc +86-21-54920910 apan@sibs.ac.cn
Contact: Ling Lu, MSc +86-21-54920910 llu01@sibs.ac.cn
China
 
NCT00742742
CWC-2008, KSCX1-YW-02
No
Xu Lin, Principal Investigator, Institute for Nutritional Sciences, Chinese Academy of Sciences
Chinese Academy of Sciences
California Walnut Commission
Principal Investigator: Xu Lin, MD, PhD Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences
Chinese Academy of Sciences
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP